Investing in the future of health: BioScience Managers and Maxis launch health technology fund in Türkiye

BioScience Managers (BSM), in partnership with Maxis, a leading venture capital platform and a subsidiary of Türkiye İş Bankası, Türkiye’s largest private bank, announced the establishment of a new health technology investment fund focusing on the Türkiye bioscience sector.  The BioScience Managers Türkiye BioScience Investment Fund, with a target raise of USD 100M, is expected to be a huge milestone for the country’s innovation and investment landscape as the first foreign-backed fund in Türkiye dedicated exclusively to health technologies. 

The fund is designed to invest between USD 5-10 million in each portfolio company, with a target of supporting 10-12 high-potential ventures. Through these investments, the fund aims to strengthen Türkiye’s global competitiveness accelerating the development and commercialisation of transformative health solutions. 

Strategic Partnership driving global health innovation 

The fund has been established under the management of Maxis Venture Capital, with BSM providing strategic guidance based on its more than 20 years of international experience in health and life sciences investment. Together, BSM and Maxis bring complementary strengths: global sector expertise, disciplined fund management, and deep local market insight. Guests were welcomed financial and life sciences industry leaders: İş Bankası’s Deputy General Manager Sezgin Lüle, Maxis Venture Capital’s General Manager Özgür Temel, BioScience Managers’ Managing Partner Jeremy Curnock Cook, and BioScience Managers’ Türkiye Managing Partner Dr. Işıl Güney. The event was also attended BSM’s Dr. Amanda Gillon and Dr. Geoff Brooke, UCLA’s Chancellor’s Prof. Aydoğan Özcan, Intergen CEO Prof. Serdar Ceylaner, innovators, and members of BSM’s investment portfolio: Adherium’s Board Member Keven Gessner, Canary Medical’s CEO Dr. Bill Hunter, and Cynata Therapeutics’ CEO Dr. Killian Kelly. 

Sezgin Lüle highlighted the fund as a strong indicator of international confidence in Türkiye’s innovation capability, noting “This fund is a significant step for the future of transformative solutions in health technologies as much as it is for the entrepreneurship ecosystem. Through this fund, which we view as an investment in the future, we aim to contribute to Türkiye’s journey from being a consumer of technology to becoming a global producer.” 

Dr. Işıl Güney emphasised the BSM team’s long-standing track record in health and bioscience investments, with more than 200 health-related investments globally and leadership in over 40 public offerings and mergers. “We will invest in Türkiye’s strong potential in the healthcare technology space, help shape the future of medicine, and create lasting value transforming innovative companies into commercially sustainable global businesses. Launching this fund in partnership with Maxis, we are pleased to collaborate with a leading institution in Türkiye and excited to begin this journey with such significant potential.” 

Maxis Venture Capital’s General Manager Özgür Temel, also noted how the fund marks a milestone for the Turkish entrepreneurship ecosystem. “Today, we are witnessing an important milestone for our country’s entrepreneurship ecosystem. We are excited not only to provide financing to startups founded Turkish entrepreneurs, but also to create a significant know-how transfer opportunity partnering with a group that has achieved major global successes in health and life sciences technologies. As the İş Bankası Group’s specialized subsidiary in this field, we believe that this year we have created substantial added value for the ecosystem through both our investments and the funds we have launched.” 

The fund will focus on high-growth segments including digital health, biotechnology, gene medicines, and medical technologies. By combining Türkiye’s strong healthcare infrastructure and highly skilled scientific and clinical talent with global investment and management expertise, the fund seeks to enable the development of transformative health solutions. 

If you’re interested in learning more about the Türkiye BioScience Investment Fund, please send an email to info@biosciencemanagers.com. 

Read more stories about the launch. 

Media Coverage: